Michael Mullan has a PhD in Philosophy but is best known for his important research in the field of Molecular Genetics. His area of specialty lies in disorders of the brain, such as Alzheimer's disease, and Neurodegenerative disorders and he continues to study and lecture on these subjects. He is the CEO of the Roskamp Institute, where he directs the Memory Disorder Clinic. The Roskamp Institute is dedicated to finding a cure for neuropsychiatric and neurodegenerative disorders as well as addictions, with a strong emphasis on Alzheimer's disease. Based in Sarasota, Florida, the organization makes use of a wide range of scientific methodologies to delve deeply into the possible causes and cures for all of these disorders. By targeting his research on the discovery of safe and effective drug therapies, Michael Mullan works to discover successful treatments to help encourage and promote healthy ways of aging. Michael Mullan currently serves as Chairman of the Board at Star Scientific Inc, Chief Executive Officer of the Roskamp Institute, the CEO and Chief Scientific Officer of Archer Pharmaceuticals, Inc., and President of Sci-Brain.
Studies and Credentials
Born in Farnborough, Kent in 1956, Michael Mullan studied for a degree in medicine at London University. He was awarded the Hoechst Elective Award for Genetic Studies at the Institute of Psychiatry in 1984 and he graduated with an MBBS in 1985. He earned an MRCPsych at the Royal College of Psychiatrist in 1990 and was awarded many prizes along the way. In 1987 he was given the Ethel Williams Scholarship by the Royal Free Hospital for his postgraduate research involving Alzheimer's disease. The same year he was given the Bethlem and Maudsley Special Health Authority Research Registrar posting for his molecular genetic and clinical studies into Familial Alzheimer's disease. The following three years he received a Clinical Research Fellowship from the Mental Health Foundation to research the clinicogenetic correlates that exist in Familial Alzheimer's disease, which provided for special teaching in the techniques involved with molecular genetics and statistical analysis. Continuing his studies, he earned a Doctorate in Philosophy in Molecular Genetics from London University in 1993. He was the Principal Investigator into the "Genetics of Schizophrenia" and "Genetics of Alcoholism" during those years of study. He also received a Mental Health Foundation grant to research the correlation between the amyloid precursor protein locus and late onset of Alzheimer's.
In 1998 Michael Mullan took a position as Senior Registrar for the Royal Free Hospital and Friern Hospital, which he continued for three years. During that time, he was the House Physician for Harrogate General and District Hospitals as well as the Royal East Sussex Hospital. He worked in Adult Psychiatry at Friern Hospital in London as well as psycho-geriatrics and rehab and worked at the Middlesex Hospital's Medical School in London. Other hospitals he worked at include the Royal Masonic Hospital, St Mary's Hospital, the National Hospital for Nervous Diseases, the Mother and Baby Unit at Bethlem Hospital and Maudsley Hospital. In 1994 he took over as director at Roskamp Laboratories and in 1995 he became the Professor in the Department of Psychiatry at Roskamp Institute until 2003, when he became President and CEO of Roskamp, a position that he currently holds. In 2014